SEARCH

SEARCH BY CITATION

LITERATURE CITED

  • 1
    Wood KJ,Sakaguchi S. Regulatory T cells in transplantation tolerance. Nat Rev Immunol 2003; 3: 199210.
  • 2
    Owen RD. Immunogenetic consequences of vascular anastomoses between bovine twins. Science 1945; 102: 400401.
  • 3
    Billingham RE,Brent L,Medawar PB. Activity acquired tolerance of foreign cells. Nature 1953; 172: 603606.
  • 4
    Gershon RK,Kondo K. Infectious immunological tolerance. Immunology 1971; 21: 903914.
  • 5
    Gershon RK,Kondo K. Cell interactions in the induction of tolerance: The role of thymic lymphocytes. Immunology 1970; 18: 723737.
  • 6
    Fujimoto S,Greene M,Sehon AH. Immunosuppressor T cells in tumour bearing host. Immunol Commun 1975; 4: 201217.
  • 7
    North RJ,Bursuker I. Generation and decay of the immune response to a progressive fibrosarcoma. I. Ly-1 + 2–suppressor T cells downregulate the generation of Ly-1-2 + effector T cells. J Exp Med 1984; 159: 12951311.
  • 8
    Sakaguchi S,Sakaguchi N,Asano M,Itoh M,Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 11511164.
  • 9
    Sansom DM,Walker LS. The role of CD28 and cytotoxic T-lymphocyte antigen-4 (CTLA-4) in regulatory T-cell biology. Immunol Rev 2006; 212: 131148.
  • 10
    Takahashi T,Tagami T,Yamazaki S,Uede T,Shimizu J,Sakaguchi N,Mak TW,Sakaguchi S. Immunologic self-tolerance maintained by CD25(+)CD4(+) regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J Exp Med 2000; 192: 303310.
  • 11
    Thornton AM,Shevach EM. CD4+CD25+ immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J Exp Med 1998; 188: 287296.
  • 12
    Pandiyan P,Zheng L,Ishihara S,Reed J,Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 2007; 8: 13531362.
  • 13
    Grossman WJ,Verbsky JW,Barchet W,Colonna M,Atkinson JP,Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004; 21: 589601.
  • 14
    Gondek DC,Lu LF,Quezada SA,Sakaguchi S,Noelle RJ. Cutting edge: Contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 2005; 174: 17831786.
  • 15
    Taams LS,van Amelsfort JM,Tiemessen MM,Jacobs KM,de Jong EC,Akbar AN,Bijlsma JW,Lafeber FP. Modulation of monocyte/macrophage function by human CD4+CD25+ regulatory T cells. Hum Immunol 2005; 66: 222230.
  • 16
    Piccirillo CA,Shevach EM. Control of CD8+ T cell activation by CD4+CD25+ immunoregulatory cells. J Immunol 2001; 167: 11371140.
  • 17
    Trzonkowski P,Szmit E,Mysliwska J,Dobyszuk A,Mysliwski A. CD4+CD25+ T regulatory cells inhibit cytotoxic activity of T CD8+ and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol 2004; 112: 258267.
  • 18
    Lewkowicz P,Lewkowicz N,Sasiak A,Tchorzewski H. Lipopolysaccharide-activated CD4+CD25+ T regulatory cells inhibit neutrophil function and promote their apoptosis and death. J Immunol 2006; 177: 71557163.
  • 19
    Suri-Payer E,Amar AZ,Thornton AM,Shevach EM. CD4+CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J Immunol 1998; 160: 12121218.
  • 20
    Wu J,Yi S,Ouyang L,Jimenez E,Simond D,Wang W,Wang Y,Hawthorne WJ,O'Connell PJ. In vitro expanded human CD4+CD25+ regulatory T cells are potent suppressors of T-cell-mediated xenogeneic responses. Transplantation 2008; 85: 18411848.
  • 21
    Waldmann H,Chen TC,Graca L,Adams E,Daley S,Cobbold S,Fairchild PJ. Regulatory T cells in transplantation. Semin Immunol 2006; 18: 111119.
  • 22
    Karim M,Feng G,Wood KJ,Bushell AR. CD25+CD4+ regulatory T cells generated by exposure to a model protein antigen prevent allograft rejection: Antigen-specific reactivation in vivo is critical for bystander regulation. Blood 2005; 105: 48714877.
  • 23
    Pacholczyk R,Kern J,Singh N,Iwashima M,Kraj P,Ignatowicz L. Nonself-antigens are the cognate specificities of Foxp3+ regulatory T cells. Immunity 2007; 27: 493504.
  • 24
    Kasow KA,Chen X,Knowles J,Wichlan D,Handgretinger R,Riberdy JM. Human CD4+CD25+ regulatory T cells share equally complex and comparable repertoires with CD4+CD25- counterparts. J Immunol 2004; 172: 61236128.
  • 25
    Karim M,Kingsley CI,Bushell AR,Sawitzki BS,Wood KJ. Alloantigen-induced CD25+CD4+ regulatory T cells can develop in vivo from CD25-CD4+ precursors in a thymus-independent process. J Immunol 2004; 172: 923928.
  • 26
    Hafler DA,Kent SC,Pietrusewicz MJ,Khoury SJ,Weiner HL,Fukaura H. Oral administration of myelin induces antigen-specific TGF-β1 secreting T cells in patients with multiple sclerosis. Ann N Y Acad Sci 1997; 835: 120131.
  • 27
    Groux H,O'Garra A,Bigler M,Rouleau M,Antonenko S,de Vries JE,Roncarolo MG. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 1997; 389: 737742.
  • 28
    Collison LW,Workman CJ,Kuo TT,Boyd K,Wang Y,Vignali KM,Cross R,Sehy D,Blumberg RS,Vignali DA. The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 2007; 450: 566569.
  • 29
    Niedbala W,Wei XQ,Cai B,Hueber AJ,Leung BP,McInnes IB,Liew FY. IL-35 is a novel cytokine with therapeutic effects against collagen-induced arthritis through the expansion of regulatory T cells and suppression of Th17 cells. Eur J Immunol 2007; 37: 30213029.
  • 30
    Borsellino G,Kleinewietfeld M,Di Mitri D,Sternjak A,Diamantini A,Giometto R,Höpner S,Centonze D,Bernardi G,Dell'Acqua ML,Rossini PM,Battistini L,Rötzschke O,Falk K. Expression of ectonucleotidase CD39 by Foxp3+ Treg cells: Hydrolysis of extracellular ATP and immune suppression. Blood 2007; 110: 12251232.
  • 31
    Deaglio S,Dwyer KM,Gao W,Friedman D,Usheva A,Erat A,Chen JF,Enjyoji K,Linden J,Oukka M,Kuchroo VK,Strom TB,Robson SC. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257265.
  • 32
    Bopp T,Becker C,Klein M,Klein-Hessling S,Palmetshofer A,Serfling E,Heib V,Becker M,Kubach J,Schmitt S,Stoll S,Schild H,Staege MS,Stassen M,Jonuleit H,Schmitt E. Cyclic adenosine monophosphate is a key component of regulatory T cell-mediated suppression. J Exp Med 2007; 204: 13031310.
  • 33
    Baecher-Allan C,Brown JA,Freeman GJ,Hafler DA. CD4+CD25high regulatory cells in human peripheral blood. J Immunol 2001; 167: 12451253.
  • 34
    Peters JH,Hilbrands LB,Koenen HJ,Joosten I. Ex vivo generation of human alloantigen-specific regulatory T cells from CD4(pos)CD25(high) T cells for immunotherapy. PLoS ONE 2008; 3: e2233.
  • 35
    Hoffmann P,Boeld TJ,Eder R,Albrecht J,Doser K,Piseshka B,Dada A,Niemand C,Assenmacher M,Orsó E,Andreesen R,Holler E,Edinger M. Isolation of CD4+CD25+ regulatory T cells for clinical trials. Biol Blood Marrow Transplant. 2008; 12: 267274.
  • 36
    Taams LS,Smith J,Rustin MH,Salmon M,Poulter LW,Akbar AN. Human anergic/suppressive CD4(+)CD25(+) T cells: A highly differentiated and apoptosis-prone population. Eur J Immunol 2001; 31: 11221131.
  • 37
    Taams LS,Vukmanovic-Stejic M,Smith J,Dunne PJ,Fletcher JM,Plunkett FJ,Ebeling SB,Lombardi G,Rustin MH,Bijlsma JW,Lafeber FP,Salmon M,Akbar AN. Antigen-specific T cell suppression by human CD4+CD25+ regulatory T cells. Eur J Immunol 2002; 32: 16211630.
  • 38
    Tang Q,Bluestone JA. Regulatory T-cell physiology and application to treat autoimmunity. Immunol Rev 2006; 212: 217237.
  • 39
    Hori S,Nomura T,Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003; 299: 10571061.
  • 40
    Trzonkowski P,Zaucha JM,Mysliwska J,Balon J,Szmit E,Halaburda K,Bieniaszewska M,Mlotkowska M,Hellmann A,Mysliwski A. Differences in kinetics of donor lymphoid cells in response to G-CSF administration may affect the incidence and severity of acute GvHD in respective HLA-identical sibling recipients. Med Oncol 2004; 21: 8194.
  • 41
    Hoffmann P,Eder R,Kunz-Schughart LA,Andreesen R,Edinger M. Large-scale in vitro expansion of polyclonal human CD4(+)CD25high regulatory T cells. Blood 2004; 104: 895903.
  • 42
    Dieckmann D,Plottner H,Berchtold S,Berger T,Schuler G. Ex vivo isolation and characterization of CD4(+)CD25(+) T cells with regulatory properties from human blood. J Exp Med 2001; 193: 13031310.
  • 43
    Liu W,Putnam AL,Xu-Yu Z,Szot GL,Lee MR,Zhu S,Gottlieb PA,Kapranov P,Gingeras TR,Fazekas de St Groth B,Clayberger C,Soper DM,Ziegler SF,Bluestone JA. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006; 203: 17011711.
  • 44
    Seddiki N,Santner-Nanan B,Martinson J,Zaunders J,Sasson S,Landay A,Solomon M,Selby W,Alexander SI,Nanan R,Kelleher A,Fazekas de St Groth B. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J Exp Med 2006; 203: 16931700.
  • 45
    Fu S,Yopp AC,Mao X,Chen D,Zhang N,Chen D,Mao M,Ding Y,Bromberg JS. CD4+ CD25+ CD62+ T-regulatory cell subset has optimal suppressive and proliferative potential. Am J Transplant 2004; 4: 6578.
  • 46
    Valmori D,Merlo A,Souleimanian NE,Hesdorffer CS,Ayyoub M. A peripheral circulating compartment of natural naive CD4 Tregs. J Clin Invest 2005; 115: 19531962.
  • 47
    Hoffmann P,Eder R,Boeld TJ,Doser K,Piseshka B,Andreesen R,Edinger M. Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 2006; 108: 42604267.
  • 48
    Koenen H,Fasse E,Joosten I. CD27/CFSE-based ex vivo selection of highly suppressive alloantigen-specific human regulatory T cells. J Immunol 2005; 174: 75737583.
  • 49
    Coenen JJ,Koenen HJ,van Rijssen E,Hilbrands LB,Joosten I. Rapamycin, and not cyclosporin A, preserves the highly suppressive CD27+ subset of human CD4+CD25+ regulatory T cells. Blood 2006; 107: 10181023.
  • 50
    Read S,Malmstrom V,Powrie F. CTLA4 plays an essential role in the function of CD25+CD4+ regulatory cells that control intestinal inflammation. J Exp Med 2000; 192: 295302.
  • 51
    Trzonkowski P,Szmit E,Mysliwska J,Mysliwski A. CD4+CD25+ T regulatory cells inhibit cytotoxic activity of CTL and NK cells in humans-impact of immunosenescence. Clin Immunol 2006; 119: 307316.
  • 52
    Mizobuchi T,Yasufuku K,Zheng Y,Haque MA,Heidler KM,Woods K,Smith GN,Cummings OW,Fujisawa T,Blum JS,Wilkes DS. Differential expression of Smad7 transcipts identifies the CD4+CD25+CD45RChigh regulatory T cells that mediate type V collagen-induced tolerance to lung allografts. J Immunol 2003; 171: 11401147.
  • 53
    Strickland DH,Stumbles PA,Zosky GR,Subrata LS,Thomas JA,Turner DJ,Sly PD,Holt PG. Reversal of airway hyperresponsiveness by induction of airway mucosal CD4+CD25+ regulatory T cells. J Exp Med 2006; 203: 26492660.
  • 54
    Stassen M,Fondel S,Bopp T,Richter C,Muller C,Kubach J,Becker C,Knop J,Enk AH,Schmitt S,Schmitt E,Jonuleit H. Human CD25+ regulatory T cells: Two subsets defined by the integrins α4 β7 or α4 β1 confer distinct suppressive properties upon CD4+ T helper cells. Eur J Immunol 2004; 34: 13031311.
  • 55
    Marski M,Kandula S,Turner JR,Abraham C. CD18 is required for optimal development and function of CD4+CD25+ T regulatory cells. J Immunol 2005; 175: 78897897.
  • 56
    Ji J,Masterson J,Sun J,Soong L. CD4+CD25+ regulatory T cells restrain pathogenic responses during Leishmania amazonesis infection. J Immunol 2005; 174: 71477153.
  • 57
    Zheng Y,Manzotti M,Liu M,Burke F,Mead KI,Sansom DM. CD86 and Cd80 differentially modulate the suppressive function of human Tregs. J Immunol 2004; 172: 27782784.
  • 58
    Fritzsching B,Oberle N,Eberhardt N,Quick S,Haas J,Wildemann B,Krammer PH,Suri-Payer E. In contrast to effector cells, CD4+CD25+FoxP3+ regulatory T cells are highly susceptible to CD95 ligand - but not TCR mediated cell death. J Immunol 2005; 175: 3236.
  • 59
    Zhao DM,Thornton AM,DiPaolo RJ,Shevach EM. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood 2006; 107: 39253932.
  • 60
    Venet F,Pachot A,Debart Al,Bohe J,Bienvenu J,Lepape A,Powell WS,Moneret G. Human CD4+CD25+ regulatory T lymphocytes inhibit LPS induced monocyte survival through Fas/FasL dependent mechanism. J Immunol 2006; 177: 65406547.
  • 61
    Soper DM,Kasprowicz DJ,Ziegler SF. IL2R-β links IL2R signaling with FoxP3 expression. Eur J Immunol 2007; 37: 18171826.
  • 62
    Sanchez J,Casano J,Alvarez MA,Roman-Gomez J,Martin C,Martinez F,Gomez P,Serrano J,Herrera C,Torres A. Kinetic of regulatory CD25high and activated CD134+ (OX40+) T lymphocytes during acute and chronic GVHD after allogeneic bone marrow transplantation. Br J Haematol 2004; 126: 697703.
  • 63
    Choi BK,Bae JS,Choi EM,Kang WJ,Sakaguchi S,Vinay DS,Kwon BS. 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. J Leukoc biol 2004; 75: 785791.
  • 64
    McHugh, RSWhitters MJ,Piccirillo CA,Young DA,Shevach EM,Collins M,Byrne MC. CD4+CD25+ immunoregulatory T cells: Gene expression analysis reveals a functional role for GITR. Immunity 2002; 16: 311323.
  • 65
    Jarvien IZ,Blazar BR,Adei OA,Strom TB,Noelle RJ. CD154 on the surface of CD4+CD25+ regulatory T cells contributes to skin transplant tolerance. Transplantation 2003; 76: 13751379.
  • 66
    van Maurik A,Herber M,Wood KJ,Jones ND. CD4+CD25+ alloantigen specific immunoregulatory cells that can prevent CD8+ T cell mediated graft rejection: Implications for anti-CD154 immunothrapy. J Immunol 2002; 169: 54015404.
  • 67
    Ghiringhelli F,Ménard C,Terme M,Flament C,Taieb J,Chaput N,Puig PE,Novault S,Escudier B,Vivier E,Lecesne A,Robert C,Blay JY,Bernard J,Caillat-Zucman S,Freitas A,Tursz T,Wagner-Ballon O,Capron C,Vainchencker W,Martin F,Zitvogel L. CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-β-dependent manner. J Exp Med 2005; 202: 10751085.
  • 68
    Salomon B,Lenschow DJ,Rhee L,Ashourian N,Singh B,Sharpe A,Bluestone JA. B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes. Immunity 2000; 12: 431440.
  • 69
    Tai X,Cowan M,Feigenbaum L,Singer A. CD28 costimulation of developing thymocytes induces Foxp3 expression and regulatory T cell differentiation independently of interleukin 2. Nat Immunol 2005; 6: 152162.
  • 70
    Habicht A,Shirine D,Jurewicz M,Fife BT,Yagita H,Azuma M,Sayegh M,Guleria I. A link between PDL1 and T regulatory cells in fetomaternal tolerance J Immunol 2007; 179: 52115219.
  • 71
    Caramalho I,Lopes-Carvalho T,Ostler D,Zelenay S,Haury M,Demengeot J. Regulatory T cells selectively express toll-like receptors and are activated by lipopolysaccharide. J Exp Med 2003; 197: 403411.
  • 72
    Bruder D,Probst-Kepper M,Westendorf AM,Geffers R,Beissert S,Loser K,von Boehmer H,Buer J,Hansen W. Neuropilin-1: A surface marker of regulatory T cells. Eur J Immunol 2004; 34: 623630.
  • 73
    Iellem A,Mariani M,Lang R,Recalde H,Panina-Bordignon P,Sinigaglia F,D'Ambrosio D. Unique chemotactic response profile and specific expression of chemokine receptors CCR4 and CCR8 by CD4(+)CD25(+) regulatory T cells. J Exp Med 2001; 194: 847853.
  • 74
    Curiel TJ,Coukos G,Zou L,Alvarez X,Cheng P,Mottram P,Evdernon-Hogan M,Conejo-Garcia JR,Zhang L,Burow M,Zhu Y,Wei S,Kryczek I,Daniel B,Gordon L,Myers L,Lackner A,Disis ML,Knutson KL,Chen L,Zou W. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004; 10: 942949.
  • 75
    Ardalan MR,Maljaei H,Shoja MM,Piri AR,Khosroshahi HT,Noshad H,Argani H. Calcitriol started in the donor, expands the population of CD4+CD25+ T cells in renal transplant recipients. Transplant Proc 2007; 39: 951953.
  • 76
    Game DS,Hernandez-Fuentes MP,Lechler RI. Everolimus and basiliximab permit suppression by human CD4+CD25+ cells in vitro. Am J Transplant 2005; 5: 454464.
  • 77
    Trzonkowski P,Zilvetti M,Chapman S,Wieckiewicz J,Sutherland A,Friend P,Wood KJ. Homeostatic repopulation by CD28-CD8+ T cells in alemtuzumab-depleted kidney transplant recipients treated with reduced immunosuppression. Am J Transplant 2008; 8: 338347.
  • 78
    Basu S,Golovina T,Mikheeva T,June CH,Riley JL. Cutting edge: Foxp3-mediated induction of pim 2 allows human T regulatory cells to preferentially expand in rapamycin. J Immunol 2008; 180: 57945798.
  • 79
    Segundo DS,Ruiz JC,Izquierdo M,Fernández-Fresnedo G,Gómez-Alamillo C,Merino R,Benito MJ,Cacho E,Rodrigo E,Palomar R,López-Hoyos M,Arias M. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation 2006; 82: 550557.
  • 80
    Zeiser R,Nguyen VH,Beilhack A,Buess M,Schulz S,Baker J,Contag CH,Negrin RS. Inhibition of CD4+CD25+ regulatory T-cell function by calcineurin-dependent interleukin-2 production. Blood 2006; 108: 390399.
  • 81
    Suárez A,López P,Gómez J,Gutiérrez C. Enrichment of CD4+ CD25high T cell population in patients with systemic lupus erythematosus treated with glucocorticoids. Ann Rheum Dis 2006; 65: 15121517.
  • 82
    Chen X,Oppenheim JJ,Winkler-Pickett RT,Ortaldo JR,Howard OM. Glucocorticoid amplifies IL-2-dependent expansion of functional FoxP3(+)CD4(+)CD25(+) T regulatory cells in vivo and enhances their capacity to suppress EAE. Eur J Immunol 2006; 36: 21392149.
  • 83
    Kreijveld E,Koenen HJ,Klasen IS,Hilbrands LB,Joosten I. Following anti-CD25 treatment, a functional CD4+CD25+ regulatory T-cell pool is present in renal transplant recipients. Am J Transplant 2007; 7: 249255.
  • 84
    Watanabe T,Masuyama J,Sohma Y,Inazawa H,Horie K, Kojima K CD52 is a novel costimulatory molecule for induction of CD4+ regulatory T-cells. Clin Immunol 2006; 120: 247259.
  • 85
    Ciancio G,Burke GW,Gaynor JJ,Carreno MR,Cirocco RE,Mathew JM. A randomized trial of three renal transplant induction antibodies: Early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005; 80: 457465.
  • 86
    Lopez M,Clarkson MR,Albin M,Sayegh MH,Najafian N. A novel mechanism of action for anti-thymocyte globulin: Induction of CD4+CD25+Foxp3+ regulatory T cells. J Am Soc Nephrol 2006; 17: 28442853.
  • 87
    Feng X,Kajigaya S,Solomou EE,Keyvanfar K,Xu X,Raghavachari N,Munson PJ,Herndon TM,Chen J,Young NS. Rabbit ATG but not horse ATG promotes expansion of functional CD4+CD25highFOXP3+ regulatory T cells in vitro. Blood 2008; 111: 36753683.
  • 88
    Valencia X,Stephens G,Goldbach-Mansky R,Wilson M,Shevach EM,Lipsky PE. TNF downmodulates the function of human CD4+CD25hi T-regulatory cells. Blood 2006; 108: 253261.
  • 89
    Ehrenstein MR,Evans JG,Singh A,Moore S,Warnes G,Isenberg DA,Mauri C. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J Exp Med 2004; 200: 277285.
  • 90
    Malek TR. The main function of IL-2 is to promote the development of T regulatory cells. J Leukoc Biol 2003; 74: 961965.
  • 91
    Ghiringhelli F,Larmonier N,Schmitt E,Parcellier A,Cathelin D,Garrido C,Chauffert B,Solary E,Bonnotte B,Martin F. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur J Immunol 2004; 34: 336344.
  • 92
    Beyer M,Kochanek M,Darabi K,Popov A,Jensen M,Endl E,Knolle PA,Thomas RK,von Bergwelt-Baildon M,Debey S,Hallek M,Schultze JL. Reduced frequencies and suppressive function of CD4+CD25hi regulatory T cells in patients with chronic lymphocytic leukemia after therapy with fludarabine. Blood 2005; 106: 20182025.
  • 93
    Polanczyk MJ,Hopke C,Vandenbark AA,Offner H. Estrogen-mediated immunomodulation involves reduced activation of effector T cells, potentiation of Treg cells, and enhanced expression of the PD-1 costimulatory pathway. J Neurosci Res 2006; 84: 370378.
  • 94
    Polanczyk MJ,Hopke C,Huan J,Vandenbark AA,Offner H. Enhanced FoxP3 expression and Treg cell function in pregnant and estrogen-treated mice. J Neuroimmunol 2005; 170: 8592.
  • 95
    Benson MJ,Pino-Lagos K,Rosemblatt M,Noelle RJ. All-trans retinoic acid mediates enhanced T reg cell growth, differentiation, and gut homing in the face of high levels of co-stimulation. J Exp Med 2007; 204: 17651774.
  • 96
    Cozzo C,Larkin JIII,Caton AJ. Cutting edge: Self-peptides drive the peripheral expansion of CD4+CD25+ regulatory T cells. J Immunol 2003; 171: 56785682.
  • 97
    Houtz B,Trotter J,Sasaki D. Tips on cell preparation for flow cytometric analysis and sorting. BD facsserivce technote 2004; 9: 14.
  • 98
    Gottenberg JE,Lavie F,Abbed K,Gasnault J,Le Nevot E,Delfraissy JF,Taoufik Y,Mariette X. CD4 CD25high regulatory T cells are not impaired in patients with primary Sjögren's syndrome. J Autoimmun 2005 24: 235242.
  • 99
    Cao D,van Vollenhoven R,Klareskog L,Trollmo C,Malmström V. CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease. Arthritis Res Ther 2004; 6: R335R346.
  • 100
    Godfrey WR,Ge YG,Spoden DJ,Levine BL,June CH,Blazar BR,Porter SB. In vitro-expanded human CD4(+)CD25(+) T-regulatory cells can markedly inhibit allogeneic dendritic cell-stimulated MLR cultures. Blood 2004; 104: 453456.
  • 101
    Taylor PA,Lees CJ,Blazar BR. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002; 99: 34933499.
  • 102
    Lin CH,Hünig T. Efficient expansion of regulatory T cells in vitro and in vivo with a CD28 superagonist. Eur J Immunol 2003; 33: 626638.
  • 103
    Beyersdorf N,Balbach K,Hünig T,Kerkau T. Large-scale expansion of rat CD4+ CD25+ T(reg) cells in the absence of T-cell receptor stimulation. Immunology 2006; 119: 441450.
  • 104
    Suntharalingam G,Perry MR,Ward S,Brett SJ,Castello-Cortes A,Brunner MD,Panoskaltsis N. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN 1412. N Engl J Med 2006; 355: 10181028.
  • 105
    Masuyama J,Kaga S,Kano S,Minota S. A novel costimulation pathway via the 4C8 antigen for the induction of CD4+ regulatory T cells. J Immunol 2002; 169: 37103716.
  • 106
    Choi BK,Bae JS,Choi EM,Kang WJ,Sakaguchi S,Vinay DS,Kwon BS. 4-1BB-dependent inhibition of immunosuppression by activated CD4+CD25+ T cells. J Leukoc Biol 2004; 75: 785791.
  • 107
    Elpek KG,Yolcu ES,Franke DD,Lacelle C,Schabowsky RH,Shirwan H. Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling. J Immunol 2007; 179: 72957304.
  • 108
    Zhang P,Gao F,Wang Q,Wang X,Zhu F,Ma C,Sun W,Zhang L. Agonistic anti-4-1BB antibody promotes the expansion of natural regulatory T cells while maintaining Foxp3 expression. Scand J Immunol 2007; 66: 435440.
  • 109
    Malek TR,Yu A,Vincek V,Scibelli P,Kong L. CD4 regulatory T cells prevent lethal autoimmunity in IL-2Rbeta-deficient mice. Implications for the nonredundant function of IL-2. Immunity 2002; 17: 167178.
  • 110
    Zheng XX,Sánchez-Fueyo A,Sho M,Domenig C,Sayegh MH,Strom TB. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 2003; 19: 503514.
  • 111
    Nelson BH. IL-2, regulatory T cells, and tolerance. J Immunol. 2004; 172: 39833988.
  • 112
    Thornton AM,Donovan EE,Piccirillo CA,Shevach EM. Cutting edge: IL-2 is critically required for the in vitro activation of CD4+CD25+ T cell suppressor function. J Immunol. 2004; 172: 65196523.
  • 113
    Shah MH,Freud AG,Benson DMJr,Ferkitich AK,Dezube BJ,Bernstein ZP,Caligiuri MA. A phase I study of ultra low dose interleukin-2 and stem cell factor in patients with HIV infection or HIV and cancer. Clin Cancer Res 2006; 12: 39933996.
  • 114
    Zhang H,Chua KS,Guimond M,Kapoor V,Brown MV,Fleisher TA,Long LM,Bernstein D,Hill BJ,Douek DC,Berzofsky JA,Carter CS,Read EJ,Helman LJ,Mackall CL. Lymphopenia and interleukin-2 therapy alter homeostasis of CD4+CD25+ regulatory T cells. Nat Med 2005; 11: 12381243.
  • 115
    Koenen HJ,Fasse E,Joosten I. IL-15 and cognate antigen successfully expand de novo-induced human antigen-specific regulatory CD4+ T cells that require antigen-specific activation for suppression. J Immunol 2003; 171: 64316441.
  • 116
    Karakhanova S,Munder M,Schneider M,Bonyhadi M,Ho AD,Goerner M. Highly efficient expansion of human CD4+CD25+ regulatory T cells for cellular immunotherapy in patients with graft-versus-host disease. J Immunother 2006; 29: 336349.
  • 117
    Wolf D,Rumpold H,Koppelstätter C,Gastl GA,Steurer M,Mayer G,Gunsilius E,Tilg H,Wolf AM. Telomere length of in vivo expanded CD4(+)CD25 (+) regulatory T-cells is preserved in cancer patients. Cancer Immunol Immunother 2006; 55: 11981208.
  • 118
    Strauss L,Whiteside TL,Knights A,Bergmann C,Knuth A,Zippelius A. Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol 2007; 178: 320329.
  • 119
    Keever-Taylor CA,Browning MB,Johnson BD,Truitt RL,Bredeson CN,Behn B,Tsao A. Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis. Cytotherapy 2007; 9: 14457.
  • 120
    Ochando JC,Yopp AC,Yang Y,Garin A,Li Y,Boros P,Llodra J,Ding Y,Lira SA,Krieger NR,Bromberg JS. Lymph node occupancy is required for the peripheral development of alloantigen-specific Foxp3+ regulatory T cells. J Immunol 2005; 174: 69937005.
  • 121
    Samy ET,Parker LA,Sharp CP,Tung KS. Continuous control of autoimmune disease by antigen-dependent polyclonal CD4+CD25+ regulatory T cells in the regional lymph node. J Exp Med 2005; 202: 771781.
  • 122
    Neujahr DC,Chen C,Huang X,Markmann JF,Cobbold S,Waldmann H,Sayegh MH,Hancock WW,Turka LA. Accelerated memory cell homeostasis during T cell depletion and approaches to overcome it. J Immunol 2006; 176: 46324639.
  • 123
    Wan S,Xia C,Morel L. IL-6 produced by dendritic cells from lupus-prone mice inhibits CD4+CD25+ T cell regulatory functions. J Immunol 2007; 178: 271279.
  • 124
    Xu L,Kitani A,Fuss I,Strober W. Regulatory T cells induce CD4+CD25-Foxp3- Tcells or are self-induced to become Th17 cells in the absence of exogenous TGF-β. J Immunol 2007; 178: 67256729.
  • 125
    Crellin NK,Garcia RV,Levings MK. Flow cytometry-based methods for studying signaling in human CD4+CD25+FOXP3+ T regulatory cells. J Immunol Methods 2007; 324: 92104.
  • 126
    Kretschmer K,Apostolou I,Hawiger D,Khazaie K,Nussenzweig MC,von Boehmer H. Inducing and expanding regulatory T cell populations by foreign antigen. Nat Immunol 2005; 6: 12191227.
  • 127
    Baron U,Floess S,Wieczorek G,Baumann K,Grützkau A,Dong J,Thiel A,Boeld TJ,Hoffmann P,Edinger M,Türbachova I,Hamann A,Olek S,Huehn J. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 2007; 37: 23782389.
  • 128
    Polansky JK,Kretschmer K,Freyer J,Floess S,Garbe A,Baron U,Olek S,Hamann A,von Boehmer H,Huehn J. DNA methylation controls Foxp3 gene expression. Eur J Immunol 2008; 38: 16541663.
  • 129
    Floess S,Freyer J,Siewert C,Baron U,Olek S,Polansky J,Schlawe K,Chang HD,Bopp T,Schmitt E,Klein-Hessling S,Serfling E,Hamann A,Huehn J. Epigenetic control of the foxp3 locus in regulatory T cells. PLoS Biol 2007; 5: e38.
  • 130
    Fantini MC,Becker C,Tubbe I,Nikolaev A,Lehr HA,Galle P,Neurath MF. Transforming growth factor beta induced FoxP3+ regulatory T cells suppress Th1 mediated experimental colitis. Gut 2006; 55: 671680.
  • 131
    Rao PE,Petrone AL,Ponath PD. Differentiation and expansion of T cells with regulatory function from human peripheral lymphocytes by stimulation in the presence of TGF-β. J Immunol 2005; 174: 14461455.
  • 132
    Yamagiwa S,Gray JD,Hashimoto S,Horwitz DA. A role for TGF-beta in the generation and expansion of CD4+CD25+ regulatory T cells from human peripheral blood. J Immunol 2001; 166: 72827289.
  • 133
    Battaglia M,Roncarolo MG. In vivo neutralization of inflammatory cytokines might not be necessary for regulatory T-cell immunotherapy. Nat Rev Immunol 2008; 8. doi:10.1038/nri2138-c2.
  • 134
    Trenado A,Sudres M,Tang Q,Maury S,Charlotte F,Grégoire S,Bonyhadi M,Klatzmann D,Salomon BL,Cohen JL. Ex vivo-expanded CD4+CD25+ immunoregulatory T cells prevent graft-versus-host-disease by inhibiting activation/differentiation of pathogenic T cells. J Immunol 2006; 176: 266273.
  • 135
    Hayashi Y,Tsukumo S,Shiota H,Kishihara K,Yasutomo K. Antigen-specific T cell repertoire modification of CD4+CD25+ regulatory T cells. J Immunol 2004; 172: 52405248.
  • 136
    Tang Q,Henriksen KJ,Bi M,Finger EB,Szot G,Ye J,Masteller EL,McDevitt H,Bonyhadi M,Bluestone JA. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004; 199: 14551465.
  • 137
    Trenado A,Charlotte F,Fisson S,Yagello M,Klatzmann D,Salomon BL,Cohen JL. Recipient-type specific CD4+CD25+ regulatory T cells favor immune reconstitution and control graft-versus-host disease while maintaining graft-versus-leukemia. J Clin Invest 2003; 112: 16881696.
  • 138
    Jiang S,Camara N,Lombardi G,Lechler RI. Induction of allopeptide-specific human CD4+CD25+ regulatory T cells ex vivo. Blood 2003; 102: 21802186.
  • 139
    Battaglia M,Gregori S,Bacchetta R,Roncarolo MG. Tr1 cells: From discovery to their clinical application. Semin Immunol 2006; 18: 120127.
  • 140
    Yamazaki S,Inaba K,Tarbell KV,Steinman RM. Dendritic cells expand antigen-specific Foxp3+ CD25+ CD4+ regulatory T cells including suppressors of alloreactivity. Immunol Rev 2006; 212: 314329.
  • 141
    Munn DH,Mellor AL. Indoleamine 2,3-dioxygenase and tumor-induced tolerance. J Clin Invest 2007; 117: 11471154.
  • 142
    Mellor AL,Baban B,Chandler P,Marshall B,Jhaver K,Hansen A,Koni PA,Iwashima M,Munn DH. Induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J Immunol 2003; 171: 16521655.
  • 143
    Steinbrink K,Jonuleit H,Muller G,Schuler G,Knop J,Enk AH. IL10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8+ T cells resulting in a failure to lyse tumor cells. Blood 1999; 93: 16341645.
  • 144
    Vigoroux S,Yvon E,Biagi E,Brenner MK. Antigen-induced regulatory T cells. Blood 2004; 104: 2633.
  • 145
    Steinbrink K,Wolfl M,Jonuleit H,Knop J,Enk AH. Induction of tolerance by IL10-treated dendritic cells. J Immunol 1997; 159: 47724782.
  • 146
    Jonuleit H,Schmitt E,Schuler G,Knop J,Enk AH. Induction of IL10-producing, nonproliferating CD4+ T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med 2000; 192: 183191.
  • 147
    Li L,Li SP,Min J,Zheng L. Hepatoma cells inhibit the differentiation and maturation of dendritic cells and increase the production of regulatory T cells. Immunol Lett 2007; 114: 3845.
  • 148
    Bayry J,Triebel F,Kaveri SV,Tough DF. Human dendritic cells acquire a semimature phenotype and lymph node homing potential through interaction with CD4+CD25+ regulatory T cells. J Immunol 2007; 178: 41844193.
  • 149
    Encabo A,Solves P,Carbonell-Uberos F,Miñana MD. The functional immaturity of dendritic cells can be relevant to increased tolerance associated with cord blood transplantation. Transfusion 2007; 47: 272279.
  • 150
    Levings MK,Gregori S,Tresoldi E,Cazzaniga S,Bonini C,Roncarolo MG. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood 2005; 105: 11621169.
  • 151
    Misra N,Bayry J,Lacroix-Desmazes S,Kazatchkine MD,Kaveri SV. Cutting edge: Human CD4+CD25+ T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol 2004; 172: 46764680.
  • 152
    Mellor AL,Chandler P,Baban B,Hansen AM,Marshall B,Pihkala J,Waldmann H,Cobbold S,Adams E,Munn DH. Specific subsets of murine dendritic cells acquire potent T cell regulatory functions following CTLA4-mediated induction of indoleamine 2,3 dioxygenase. Int Immunol 2004; 16: 13911401.
  • 153
    Munn DH,Sharma MD,Hou D,Baban B,Lee JR,Antonia SJ,Messina JL,Chandler P,Koni PA,Mellor AL. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 2004; 114: 280290.
  • 154
    Morelli AE,Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol 2007; 7: 610621.
  • 155
    Sawitzki B,Kingsley CI,Oliveira V,Karim M,Herber M,Wood KJ. IFN-gamma production by alloantigen-reactive regulatory T cells is important for their regulatory function in vivo. J Exp Med 2005; 201: 19251935.
  • 156
    Sharma MD,Baban B,Chandler P,Hou DY,Singh N,Yagita H,Azuma M,Blazar BR,Mellor AL,Munn DH. Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase. J Clin Invest 2007; 117: 25702582.
  • 157
    Munn DH,Sharma MD,Mellor AL. Ligation of B7-1/B7-2 by human CD4+ T cells triggers indoleamine 2,3-dioxygenase activity in dendritic cells. J Immunol 2004; 172: 41004110.
  • 158
    Hill M,Tanguy-Royer S,Royer P,Chauveau C,Asghar K,Tesson L,Lavainne F,Rémy S,Brion R,Hubert FX,Heslan M,Rimbert M,Berthelot L,Moffett JR,Josien R,Grégoire M,Anegon I. IDO expands human CD4+CD25high regulatory T cells by promoting maturation of LPS-treated dendritic cells. Eur J Immunol 2007; 37: 30543062.
  • 159
    Munn DH,Sharma MD,Lee JR,Jhaver KG,Johnson TS,Keskin DB,Marshall B,Chandler P,Antonia SJ,Burgess R,Slingluff CLJr,Mellor AL. Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase. Science 2002; 297: 18671870.
  • 160
    Hong J,Gong ZJ. Human plasmacytoid dendritic cells from patients with chronic hepatitis B virus infection induce the generation of a higher proportion of CD4(+) and CD25(+) regulatory T cells compared with healthy patients. Hepatol Res 2008; 38: 362373.
  • 161
    Banerjee DK,Dhodapkar MV,Matayeva E,Steinman RM,Dhodapkar KM. Expansion of FOXP3high regulatory T cells by human dendritic cells (DCs) in vitro and after injection of cytokine-matured DCs in myeloma patients. Blood 2006; 108: 26552661.
  • 162
    Moreau A,Chiffoleau E,Beriou G,Deschamps JY,Heslan M,Ashton-Chess J,Rolling F,Josien R,Moullier P,Cuturi MC,Alliot-Licht B. Superiority of bone marrow-derived dendritic cells over monocyte-derived ones for the expansion of regulatory T cells in the macaque. Transplantation 2008; 85: 13511356.
  • 163
    Larmonier N,Marron M,Zeng Y,Cantrell J,Romanoski A,Sepassi M,Thompson S,Chen X,Andreansky S,Katsanis E. Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother 2007; 56: 4859.
  • 164
    Houot R,Perrot I,Garcia E,Durand I,Lebecque S. Human CD4+CD25high regulatory T cells modulate myeloid but not plasmacytoid dendritic cells activation. J Immunol 2006; 176: 52935298.
  • 165
    Mahnke K,Qian Y,Knop J,Enk AH. Induction of CD4+/CD25+ regulatory T cells by targeting of antigens to immature dendritic cells. Blood 2003; 101: 48624869.
  • 166
    Bonifaz L,Bonnyay D,Mahnke K,Rivera M,Nussenzweig MC,Steinman RM. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J Exp Med 2002; 196: 16271638.
  • 167
    Bruder D,Westendorf AM,Hansen W,Prettin S,Gruber AD,Qian Y,von Boehmer H,Mahnke K,Buer J. On the edge of autoimmunity: T-cell stimulation by steady-state dendritic cells prevents autoimmune diabetes. Diabetes 2005; 54: 33953401.
  • 168
    Jiang S,Tsang J,Game DS,Stevenson S,Lombardi G,Lechler RI. Generation and expansion of human CD4+ CD25+ regulatory T cells with indirect allospecificity: Potential reagents to promote donor-specific transplantation tolerance. Transplantation 2006; 82: 17381743.
  • 169
    Golshayan D,Jiang S,Tsang J,Garin MI,Mottet C,Lechler RI. In vitro-expanded donor alloantigen-specific CD4+CD25+ regulatory T cells promote experimental transplantation tolerance. Blood 2007; 109: 827835.
  • 170
    Asiedu CK,Goodwin KJ,Balgansuren G,Jenkins SM,Le Bas-Bernardet S,Jargal U,Neville DMJr,Thomas JM. Elevated T regulatory cells in long-term stable transplant tolerance in rhesus macaques induced by anti-CD3 immunotoxin and deoxyspergualin. J Immunol 2005; 175: 80608068.
  • 171
    Jiang S,Golshayan D,Tsang J,Lombardi G,Lechler RI. In vitro expanded alloantigen-specific CD4+CD25+ regulatory T cell treatment for the induction of donor-specific transplantation tolerance. Int Immunopharmacol 2005; 6: 18791882.
  • 172
    George TC,Bilsborough J,Viney JL,Norment AM. High antigen dose and activated dendritic cells enable Th cells to escape regulatory T cell-mediated suppression in vitro. Eur J Immunol 2003; 33: 502511.
  • 173
    Godfrey WR,Spoden DJ,Ge YG,Baker SR,Liu B,Levine BL,June CH,Blazar BR,Porter SB. Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood 2005; 105: 750758.
  • 174
    Hoffmann P,Ermann J,Edinger M,Fathman CG,Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. J Exp Med 2002; 196: 389399.
  • 175
    Qin S,Cobbold SP,Pope H,Elliott J,Kioussis D,Davies J,Waldmann H. “Infectious” transplantation tolerance. Science 1993; 259: 974977.
  • 176
    Anastasi E,Campese AF,Bellavia D,Bulotta A,Balestri A,Pascucci M,Checquolo S,Gradini R,Lendahl U,Frati L,Gulino A,Di Mario U,Screpanti I. Expression of activated Notch3 in transgenic mice enhances generation of T regulatory cells and protects against experimental autoimmune diabetes. J Immunol 2003; 171: 45044511.
  • 177
    Ostroukhova M,Qi Z,Oriss TB,Dixon-McCarthy B,Ray P,Ray A. Treg-mediated immunosuppression involves activation of the Notch-HES1 axis by membrane-bound TGF-beta. J Clin Invest 2006; 116: 9961004.
  • 178
    Samon JB,Champhekar A,Minter LM,Telfer JC,Miele L,Fauq A,Das P,Golde TE,Osborne BA. Notch1 and TGFβ1 cooperatively regulate Foxp3 expression and the maintenance of peripheral regulatory T cells. Blood 2008; 112: 18131821.
  • 179
    Chen ZM,O'Shaughnessy MJ,Gramaglia I,Panoskaltsis-Mortari A,Murphy WJ,Narula S,Roncarolo MG,Blazar BR. IL-10 and TGF-beta induce alloreactive CD4+CD25- T cells to acquire regulatory cell function. Blood 2001; 101: 50765083.
  • 180
    Dhodapkar MV,Steinman RM,Krasovsky J,Munz C,Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 2001; 193: 233238.
  • 181
    Moseman EA,Liang X,Dawson AJ,Panoskaltsis-Mortari A,Krieg AM,Liu YJ,Blazar BR,Chen W. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol 2004; 173: 44334442.
  • 182
    Barrat FJ,Cua DJ,Boonstra A,Richards DF,Crain C,Savelkoul HF,de Waal-Malefyt R,Coffman RL,Hawrylowicz CM,O'Garra A. In vitro generation of interleukin 10-producing regulatory CD4+ T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J Exp Med 2002; 195: 603616.
  • 183
    Maccario R,Podestà M,Moretta A,Cometa A,Comoli P,Montagna D,Daudt L,Ibatici A,Piaggio G,Pozzi S,Frassoni F,Locatelli F. Interaction of human mesenchymal stem cells with cells involved in alloantigen-specific immune response favors the differentiation of CD4+ T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 2005; 90: 516525.
  • 184
    Tian Y,Deng YB,Huang YJ,Wang Y. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation. Immunol Invest 2008; 37: 2942.
  • 185
    Selmani Z,Naji A,Zidi I,Favier B,Gaiffe E,Obert L,Borg C,Saas P,Tiberghien P,Rouas-Freiss N,Carosella ED,Deschaseaux F. Human leukocyte antigen-G5 secretion by human mesenchymal stem cells is required to suppress T lymphocyte and natural killer function and to induce CD4+CD25highFOXP3+ regulatory T cells. Stem Cells 2008; 26: 212222.
  • 186
    Grundström S,Cederbom L,Sundstedt A,Scheipers P,Ivars F. Superantigen-induced regulatory T cells display different suppressive functions in the presence or absence of natural CD4+CD25+ regulatory T cells in vivo. J Immunol 2003; 170: 50085017.
  • 187
    Tang W,Yang Y,Zhang F,Li YC,Zhou R,Wang JX,Zhu YN,Li XY,Yang YF,Zuo JP. Prevention of graft-versus-host disease by a novel immunosuppressant, (5R)-5-hydroxytriptolide (LLDT-8), through expansion of regulatory T cells. Int Immunopharmacol 2005; 5: 19041913.
  • 188
    Liu Y,Chen Y,Liu FQ,Lamb JR,Tam PK. Combined treatment with triptolide and rapamycin prolongs graft survival in a mouse model of cardiac transplantation. Transpl Int 2008; 21: 483494.
  • 189
    Waldmann H. Special regulatory T cell review: The suppression problem! Immunology 2008; 123: 1112.
  • 190
    Wadman M. London's disastrous drug trial has serious side effects for research. Nature 2006; 440: 388389.
  • 191
    June CH,Blazar BR. Clinical application of expanded CD4+25+ cells. Semin Immunol 2006; 18: 7888.